UroGen Pharma Ltd. (URGN)

Health Care ยท Pharmaceutical Preparations

UroGen Pharma Ltd. (URGN) is listed on Nasdaq, where its shares have traded since May 4, 2017. SentiSense covers UroGen Pharma Ltd. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Elizabeth Barrett is its chief executive officer. The company reports 291 employees, and its corporate website is www.urogen.com.

About UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Latest reported results

UroGen Pharma Ltd. reported revenue of $89.0 million for Q3 FY2026, up 223.9% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 183 institutions reported holding URGN, with 42.0 million shares worth $1.5 billion in aggregate. The largest reported holders were Rtw Investments, BlackRock and Morgan Stanley. Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter.

More on URGN

  • URGN sentiment: whether news and social coverage of UroGen Pharma Ltd. leans bullish or bearish, and the stories driving it.
  • URGN ownership: all 183 reporting institutions, plus insider and congressional trades.
  • URGN financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.

SentiSense also tracks daily options readings for UroGen Pharma Ltd.: IV rank, put/call percentile, 25-delta skew and open-interest walls.

Frequently asked questions

What does UroGen Pharma Ltd. do?

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers.

What sector is URGN in?

SentiSense classifies UroGen Pharma Ltd. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.

Where does URGN stock trade?

UroGen Pharma Ltd. (URGN) is listed on Nasdaq, where its shares have traded since May 4, 2017.

Who is the CEO of UroGen Pharma Ltd.?

Elizabeth Barrett is the chief executive officer of UroGen Pharma Ltd..